Media Coverage · December 20, 2017
Acticor Biotech announces appointment of DR Yannick Plétan as Chief Medical Officer – Biotech Finances
December 2017. Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary …
Read next in 'Media Coverage'
- ACT017 : un fragment d’anticorps dont l’ACTion antithrombotique est prometteuse !
- Novel antiplatelet could circumvent bleeding risk for stroke patients
- Experimental antiplatelet compound for acute stroke shows promise
- New drug to prevent clots clears safety hurdle
- New blood thinner may prevent stroke, without risk for bleeding